



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Dupilumab

Cat. No.:	HY-P9926
CAS No.:	1190264-60-8
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4R α) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis ^[1] .		
IC₅₀ & Target	IL-2	IL-4	IL-13
In Vitro	<p>Dupilumab suppressed mRNA expressions of genes related to activation of T cells, DCs, eosinophils, inflammatory pathways, and TH2-inducing chemokines in skin lesions. No significant reduction in IL-17A or IL-22 levels is detected, but large reductions in expression of IL-17-related genes, such as elafin (PI3), IL23p19/IL23A, and S100A8 and trends for suppression (CXCL1 and S100A7) are found with 300 mg of Dupilumab^[1].</p> <p>Major suppressions of hyperplasia-related genes (eg, K16) and reductions in expression of S100A genes are evident with 300 mg of Dupilumab by using microarrays and qRT-PCR. The changes in other critical epidermal alterations in severe atopic dermatitis (AD) skin are also measured, including significant increases in claudin and lipid product levels with 300 mg of Dupilumab. A trend of dose-dependent increases in expression of differentiation genes (LOR and FLG) is observed after adjusting for suppression of epidermal hyperplasia, as demonstrated by K16 reductions with Dupilumab^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>		

CUSTOMER VALIDATION

- EBioMedicine. 2022 Aug 3;83:104200.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Hamilton JD, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014 Dec;134(6):1293-1300.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA